var data={"title":"Sevoflurane: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sevoflurane: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6949?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sevoflurane-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sevoflurane: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220831\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Sojourn [DSC];</li>\n      <li>Ultane</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220832\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Sevorane AF;</li>\n      <li>Sojourn Sevoflurane</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220864\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        General Anesthetic, Inhalation</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220836\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Anesthesia: </b>Inhalation: Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3% with or without the concomitant use of nitrous oxide; the concentration at which amnesia and loss of awareness occur is 0.6% (Katoh 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">MAC values for surgical levels of anesthesia:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">25 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sevoflurane in oxygen: 2.6%</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sevoflurane in 65% N<sub>2</sub>0/35% oxygen: 1.4%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">40 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sevoflurane in oxygen: 2.1%</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sevoflurane in 65% N<sub>2</sub>0/35% oxygen: 1.1%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">60 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sevoflurane in oxygen: 1.7%</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sevoflurane in 65% N<sub>2</sub>0/35% oxygen: 0.9%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">80 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sevoflurane in oxygen: 1.4%</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sevoflurane in 65% N<sub>2</sub>0/35% oxygen: 0.7%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220850\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Anesthesia:</b> Inhalation: Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3% with or without the concomitant use of nitrous oxide; the concentration at which amnesia and loss of awareness occur is 0.6% (Katoh 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">MAC values for surgical levels of anesthesia:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">0 to 1 month old full-term neonates: Sevoflurane in oxygen: 3.3%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to &lt;6 months: Sevoflurane in oxygen: 3%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">6 months to &lt;1 year:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sevoflurane in oxygen: 2.8%</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sevoflurane in 65% N<sub>2</sub>0/35% oxygen: 2%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to &lt;3 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sevoflurane in oxygen: 2.8%</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sevoflurane in 60% N<sub>2</sub>0/40% oxygen: 2%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">3-12 years: Sevoflurane in oxygen: 2.5%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220837\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. MAC is reduced in the elderly (50% reduction by age 80).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22553638\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling; use with caution in patients with creatinine &gt;1.5 mg/dL (safety not established).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22553639\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling; use with caution (safety with severe hepatic impairment has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220816\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sojourn:  (250 mL [DSC]) [additive free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ultane:  (250 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic:  (100 mL, 250 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220805\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220818\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Via sevoflurane-specific calibrated vaporizers; use cautiously in low-flow or closed-circuit systems since sevoflurane is unstable and potentially toxic breakdown products have been liberated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220817\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Anesthesia:</b> Induction and maintenance of general anesthesia in adults and pediatric patients for inpatient and outpatient surgery</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220870\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ultane may be confused with Ultram</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220810\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (4% to 11%; dose-dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Agitation (7% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (25%), vomiting (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (5% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Tachycardia (2% to 6%), bradycardia (5%), hypertension (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness (9%), shivering (6%), dizziness (4%), headache (1%), hypothermia (1%), myoclonus (1%), delirium (emergence)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Sialorrhea (2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Airway obstruction (8%), laryngospasm (2% to 8%), breath-holding (2% to 5%), apnea (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acidosis, albuminuria, amblyopia, anaphylactoid reaction, anaphylaxis, atrial arrhythmia, atrial fibrillation, bigeminy, bronchospasm, cardiac arrhythmia, chest discomfort, complete atrioventricular block, confusion, conjunctivitis, crying, depression of ST segment on ECG, dysgeusia, dyspnea, extrasystoles (supraventricular), facial edema, glycosuria, hemorrhage, hepatic failure, hepatic insufficiency, hepatic necrosis, hepatitis, hepatotoxicity (idiosyncratic; Chalasani 2014), hiccups, hyperbilirubinemia, hyperglycemia, hypersensitivity reaction, hyperkalemia (pediatric patients; postoperative), hypertonia, hyperventilation, hypophosphatemia, hypoventilation, hypoxia, increased blood urea nitrogen, increased bronchial secretions, increased creatine phosphokinase, increased lactate dehydrogenase, increased liver enzymes (transient), increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum creatinine, increased serum glucose (transient), insomnia, inversion T wave on ECG, jaundice, leukocytosis (may be transient), malignant hyperthermia, myoglobinuria, nervousness, oliguria, pain, pharyngitis, pruritus, second degree atrioventricular block, seizure (rare), skin rash, stridor, syncope, thrombocytopenia, tooth enamel damage (fluorosis), urinary retention, urticaria, ventricular premature contractions, weakness, wheezing, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220821\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to sevoflurane, other halogenated anesthetics, or any component of the formulation; known or suspected susceptibility to malignant hyperthermia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Occurrence of liver dysfunction, jaundice or unexplained fever, leukocytosis, or eosinophilia after previous halogenated anesthetic administration; when general anesthesia is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220808\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Agitation/delirium: Monitor for emergence agitation or delirium (Stachnik 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Postoperative hepatitis or hepatic dysfunction with or without jaundice has rarely been reported; prior exposure to halogenated hydrocarbon anesthetics may increase this risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: Use of inhaled anesthetics has been associated with rare cases of perioperative hyperkalemia in pediatric patients; concomitant use of succinylcholine was associated with most of the reported cases, but not all. Patients with latent and overt neuromuscular disease (eg, Duchenne muscular dystrophy) are the most vulnerable. Other abnormalities may include elevation in CPK and myoglobinuria. Monitor closely for arrhythmias. Aggressively identify and treat hyperkalemia and resistant arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Sevoflurane produces a dose-dependent reduction in blood pressure during maintenance of anesthesia and may occur more rapidly compared to other inhaled anesthetics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased intracranial pressure: May dilate the cerebral vasculature and may, in certain conditions, increase intracranial pressure (Stachnik 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignant hyperthermia: May trigger malignant hyperthermia; some reported cases have been fatal. Use is contraindicated in patients susceptible to malignant hyperthermia such as those with certain inherited ryanodine receptor mutations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: Cases of QT prolongation in association with torsade de pointes (some fatal) have been reported with sevoflurane use; use caution when administering to patients at risk of QT prolongation (eg, concurrent use of drugs that can prolong the QT interval such as class Ia and III antiarrhythmic drugs, elderly patients, congenital QT prolongation) (Han 2010; Kang 2006; Nakao 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: Causes dose-dependent respiratory depression and blunted ventilatory response to hypoxia and hypercapnia (Golembiewski 2004). Hypoxic pulmonary vasoconstriction is blunted which may lead to increased pulmonary shunt (Miller 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: In a scientific statement from the American Heart Association, sevoflurane has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; safety with severe impairment has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment (ie, creatinine &gt;1.5 mg/dL); safety with severe impairment has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients at risk for seizures; seizures have been reported in children and young adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric neurotoxicity: In pediatric and neonatal patients &lt;3 years and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on child or fetal brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies in humans have reported various cognitive and behavioral problems, including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Occupational caution: There is no specific work exposure limit established for sevoflurane. However, the National Institute for Occupational Safety and Health (NIOSH) has recommended an 8 hour time-weighted average limit of 2 ppm for halogenated anesthetic agents in general (0.5 ppm when coupled with exposure to N<sub>2</sub>O).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Desiccated absorbents: Reaction of sevoflurane with CO<sub>2</sub> absorbents that become desiccated within circle breathing equipment can lead to formation of formaldehyde (causing respiratory irritation) and carbon monoxide; maintain fresh absorbent as per manufacturer guidelines regardless of state of colorimetric indicator. An exothermic reaction occurs when sevoflurane is exposed to CO<sub>2</sub> absorbents; this reaction is increased when the CO<sub>2</sub> absorbent becomes desiccated. Rare cases of extreme heat, smoke, and/or fire within breathing circuit have been reported. This reaction also leads to formation of a fluorinated byproduct, compound A, which has been reported to cause mild and reversible renal injury in animal studies (Gentz 2001). The theoretical risk of compound A-induced nephrotoxicity in humans may be dose- and exposure time-dependent; minimize exposure risk by not exceeding 2 MAC hours and using fresh flow rates of 1 to &lt;2 L/minute (low fresh gas flow rates maximize rebreathing of the anesthetic). Steps to help reduce the risk of these events (eg, shutting off the anesthesia machine at the end of clinical use or after any case when a subsequent extended period of nonuse is expected, routine replacement of the CO<sub>2</sub> absorbents) should be incorporated into routine practice (Miller 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220860\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2A6 (minor), CYP2B6 (minor), CYP2E1 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220811\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9887&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bambuterol: May enhance the arrhythmogenic effect of Inhalational Anesthetics. Management: Some labels recommend specifically avoiding halothane; others recommend separating administration by at least 6 hours; other bambuterol labels do not mention this possible interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2E1 Inhibitors (Moderate): May decrease the metabolism of CYP2E1 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2E1 Inhibitors (Strong): May decrease the metabolism of CYP2E1 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOPamine: Inhalational Anesthetics may enhance the arrhythmogenic effect of DOPamine.  Management: Avoid use of dopamine in patients receiving halogenated hydrocarbon anesthetics.  If concomitant treatment cannot be avoided, monitor for arrhythmia.  Dopamine induced ventricular arrhythmia may be reversible with propranolol based on animal data.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ephedra: May enhance the arrhythmogenic effect of Inhalational Anesthetics.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPHEDrine (Nasal): May enhance the arrhythmogenic effect of Inhalational Anesthetics.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPHEDrine (Systemic): May enhance the arrhythmogenic effect of Inhalational Anesthetics.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPINEPHrine (Nasal): Inhalational Anesthetics may enhance the arrhythmogenic effect of EPINEPHrine (Nasal). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPINEPHrine (Oral Inhalation): Inhalational Anesthetics may enhance the arrhythmogenic effect of EPINEPHrine (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPINEPHrine (Systemic): Inhalational Anesthetics may enhance the arrhythmogenic effect of EPINEPHrine (Systemic).  Management: Administer epinephrine with added caution in patients receiving, or who have recently received, inhalational anesthetics. Use lower than normal doses of epinephrine and monitor for the development of cardiac arrhythmias.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fenoterol: Inhalational Anesthetics may enhance the arrhythmogenic effect of Fenoterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Formoterol: Inhalational Anesthetics may enhance the arrhythmogenic effect of Formoterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoproterenol: Inhalational Anesthetics may enhance the arrhythmogenic effect of Isoproterenol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaraminol: Inhalational Anesthetics may enhance the arrhythmogenic effect of Metaraminol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the hypertensive effect of Inhalational Anesthetics.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Inhalational Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Norepinephrine: Inhalational Anesthetics may enhance the arrhythmogenic effect of Norepinephrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May enhance the adverse/toxic effect of Inhalational Anesthetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14079770\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Based on animal data, repeated or prolonged use of general anesthetic and sedation medications that block N-methyl-D- aspartate (NMDA) receptors and/or potentiate gamma-aminobutyric acid (GABA) activity, may affect brain development. Human fetuses may be most vulnerable during the third trimester. Until additional information is available, the benefits and risks of maternal treatment with sevoflurane during pregnancy should be evaluated, especially for procedures lasting more than 3 hours. The ACOG recommends that pregnant women should not be denied medically indicated surgery or procedures, regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220823\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Due to rapid washout, sevoflurane levels in breast milk have no clinical importance 24 hours after anesthesia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220814\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, temperature, heart rate and rhythm, oxygen saturation, end-tidal CO<sub>2</sub> and end-tidal sevoflurane concentrations should be monitored prior to and throughout anesthesia; temperature of CO<sub>2</sub> absorbent canister</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F864323\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhaled anesthetics alter activity of neuronal ion channels particularly the fast synaptic neurotransmitter receptors (nicotinic acetylcholine, GABA, and glutamate receptors). Limited effects on sympathetic stimulation including cardiovascular system. Sevoflurane does not cause respiratory irritation or circulatory stimulation. May depress myocardial contractility, decrease blood pressure through a decrease in systemic vascular resistance and decrease sympathetic nervous activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220820\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Sevoflurane has a low blood/gas partition coefficient and therefore is associated with a rapid onset of anesthesia and recovery </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Onset of action: Time to induction: Within 2 to 3 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Emergence time: Depends on blood concentration when sevoflurane is discontinued. The rate of change of anesthetic concentration in the lung is rapid with sevoflurane because of its low blood gas solubility (0.63). The 90% decrement time (time required for anesthetic concentration in vessel-rich tissues to decrease by 90%) for sevoflurane is short when the duration of anesthesia is &lt;2 hours but increases dramatically as the duration of administration is lengthened (Bailey, 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (~5%) via CYP2E1 </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Exhaled gases</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220824\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Floves (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Haluran (SA);</li>\n      <li>Sefether (TH);</li>\n      <li>Sevo (PH, TH);</li>\n      <li>Sevocris (PY);</li>\n      <li>Sevodex (ID);</li>\n      <li>Sevofran (KR);</li>\n      <li>Sevofrane (CN, JP);</li>\n      <li>Sevoran (BD, LU, LV, RU, UA);</li>\n      <li>Sevorane (AR, AT, AU, BG, BO, BR, CH, CL, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GR, GT, HK, HN, HR, HU, ID, IE, IL, IS, IT, KR, KW, LK, LT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, PY, RO, SE, SG, SI, SK, SV, TH, TR, UY, VE, VN);</li>\n      <li>Sojourn (ID, IL, KW, PH, QA, SA, SG, TH);</li>\n      <li>Ultane (TW, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 474: nonobstetric surgery during pregnancy. <i>Obstet Gynecol</i>. 2011 ;117(2, pt 1):420-421. doi: 10.1097/AOG.0b013e31820eede9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/21252774/pubmed\" target=\"_blank\" id=\"21252774\">21252774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey JM. Context-sensitive half-times and other decrement times of inhaled anesthetics. <i>Anesth Analg</i>. 1997;85(3):681-686.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/9296431/pubmed\" target=\"_blank\" id=\"9296431\">9296431</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beck-Schimmer B, Breitenstein S, Urech S, et al, &ldquo;A Randomized Controlled Trial on Pharmacological Preconditioning in Liver Surgery Using a Volatile Anesthetic,&rdquo; <i>Ann Surg</i>, 2008, 248(6):909-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/19092335/pubmed\" target=\"_blank\" id=\"19092335\">19092335</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bein B, Renner J, Caliebe D, et al, &ldquo;The Effects of Interrupted or Continuous Administration of Sevoflurane on Preconditioning Before Cardio-Pulmonary Bypass in Coronary Artery Surgery: Comparison With Continuous Propofol,&rdquo; <i> Anaesthesia</i>, 2008, 63(10):1046-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/18627368/pubmed\" target=\"_blank\" id=\"18627368\">18627368</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Campagna JA, Miller KW, and Forman SA, &ldquo;Mechanisms of Action of Inhaled Anesthetics,&rdquo; <i>N Engl J Med</i>, 2003, 348(21):2110-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/12761368/pubmed\" target=\"_blank\" id=\"12761368\">12761368</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Hert SG, Turani F, Mathur S, et al, &ldquo;Cardioprotection With Volatile Anesthetics: Mechanisms and Clinical Implications,&rdquo; <i>Anesth Analg</i>, 2005, 100(6):1584-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/15920178 /pubmed\" target=\"_blank\" id=\"15920178 \">15920178 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doi M and Ikeda K, &ldquo;Airway Irritation Produced by Volatile Anaesthetics During Brief Inhalation: Comparison of Halothane, Enflurane, Isoflurane and Sevoflurane,&rdquo; <i>Can J Anaesth</i>, 1993, 40(2):122-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/8443850/pubmed\" target=\"_blank\" id=\"8443850\">8443850</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eger EI 2nd, &ldquo;Characteristics of Anesthetic Agents Used for Induction and Maintenance of General Anesthesia,&rdquo; <i>Am J Health Syst Pharm</i>, 2004, 61(Suppl 4):3-10.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration. FDA Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. <a href=\"https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm\" target=\"_blank\">https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm</a>. Published December 14, 2016. Accessed May 26, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frink EJ Jr, Ghantous H, Malan TP, et al, &ldquo;Plasma Inorganic Fluoride With Sevoflurane Anesthesia: Correlation With Indices of Hepatic and Renal Function,&rdquo; <i>Anesth Analg</i>, 1992, 74(2):231-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/1731542/pubmed\" target=\"_blank\" id=\"1731542\">1731542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gentz BA, Malan TP Jr. Renal toxicity with sevoflurane: a storm in a teacup? <i>Drugs</i>. 2001;61(15):2155-2162.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/11772127/pubmed\" target=\"_blank\" id=\"11772127\">11772127</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Golembiewski J, &ldquo;Considerations in Selecting an Inhaled Anesthetic Agent: Case Studies,&rdquo; <i>Am J Health Syst Pharm</i>, 2004, 61 (Suppl 4):10-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/15532144/pubmed\" target=\"_blank\" id=\"15532144\">15532144</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Han DW, Park K, Jang SB, et al, &ldquo;Modeling the Effect of Sevoflurane on Corrected QT Prolongation: A Pharmacodynamic Analysis,&rdquo; <i>Anesthesiology</i>, 2010, 113(4):108-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/20808206/pubmed\" target=\"_blank\" id=\"20808206\">20808206</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones RM, &ldquo;Desflurane and Sevoflurane: Inhalation Anaesthetics for This Decade?&rdquo; <i>Br J Anaesth</i>, 1990, 65(4):527-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/2248821/pubmed\" target=\"_blank\" id=\"2248821\">2248821</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kang J, Reynolds WP, Chen X, et al, &ldquo;Mechanisms Underlying the QT interval-prolonging Effects of Sevoflurane and Its Interactions With Other QT-prolonging Drugs,&rdquo; <i>Anesthesiology</i>, 2006, 104(5):1015-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/16645454/pubmed\" target=\"_blank\" id=\"16645454\">16645454</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katoh T, Ijeda K. The effects of fentanyl on sevoflurane requirements for loss of consciousness and skin incision. <i>Anesthesiology</i>. 1998;88(1):18-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/9447851/pubmed\" target=\"_blank\" id=\"9447851\">9447851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katoh T, Suguro Y, Nakajima R, et al, &ldquo;Blood Concentrations of Sevoflurane and Isoflurane on Recovery From Anaesthesia,&rdquo; <i>Br J Anaesth</i>, 1992, 69(3):259-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/1389843/pubmed\" target=\"_blank\" id=\"1389843\">1389843</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD. <i>Miller&rsquo;s Anesthesia</i>. 7th ed. Philadelphia, PA: Churchill Livingstone; 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nakao S, Hatano K, Sumi C, et al, &ldquo;Sevoflurane Causes Greater QTc Interval Prolongation in Elderly Patients Than in Younger Patients,&rdquo; <i>Anesth Analg</i>, 2010, 110(3):775-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/20185656/pubmed\" target=\"_blank\" id=\"20185656\">20185656</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sevorane (sevoflurane) [product monograph]. St Laurent, Quebec, Canada: AbbVie Corporation; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith I, Ding Y, and White PF, &ldquo;Comparison of Induction, Maintenance, and Recovery Characteristics of Sevoflurane-N20 and Propofol-Sevoflurane-N(2)O With Propofol-Isoflurane-N(2)O Anesthesia,&rdquo; <i>Anesth Analg</i>, 1992, 74(2):253-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/1731547/pubmed\" target=\"_blank\" id=\"1731547\">1731547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stachnik J. Inhaled anesthetic agents. <i>Am J Health-Syst Pharm</i>. 2006;63(7):623-634.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/16554286/pubmed\" target=\"_blank\" id=\"16554286\">16554286</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strum DP and Eger EI 2d, &ldquo;Partition Coefficients for Sevoflurane in Human Blood, Saline, and Olive Oil,&rdquo; <i>Anesth Analg</i>, 1987, 66(7):654-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/3605675/pubmed\" target=\"_blank\" id=\"3605675\">3605675</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ultane (sevoflurane) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang L, Traystman RJ, and Murphy SJ, &ldquo;Inhalational Anesthetics as Preconditioning Agents in Ischemic Brain,&rdquo; <i>Curr Opin Pharmacol</i>, 2008, 8(1):104-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/17962069/pubmed\" target=\"_blank\" id=\"17962069\">17962069</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yasuda N, Lockhart SH, Eger EI 2nd, et al, &ldquo;Comparison of Kinetics of Sevoflurane and Isoflurane in Humans,&rdquo; <i>Anesth Analg</i>, 1991, 72(3):316-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/1994760/pubmed\" target=\"_blank\" id=\"1994760\">1994760</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9887 Version 133.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F220831\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F220832\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F220864\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F220836\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F220850\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F220837\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22553638\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22553639\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F220816\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F220805\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F220818\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F220817\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F220870\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F220810\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F220821\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F220808\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F220860\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F220811\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14079770\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F220823\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F220814\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F864323\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F220820\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F220824\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9887|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sevoflurane-patient-drug-information\" class=\"drug drug_patient\">Sevoflurane: Patient drug information</a></li></ul></div></div>","javascript":null}